HBL - Hadasit Bio-Holdings Ltd Share Price

Equities

HDST-M

IL0010954050

Biotechnology & Medical Research

Delayed TEL AVIV STOCK EXCHANGE 12:24:09 25/04/2024 BST 5-day change 1st Jan Change
53.1 ILa 0.00% Intraday chart for HBL - Hadasit Bio-Holdings Ltd +0.19% -20.75%

Financials

Sales 2022 - Sales 2023 - Capitalization 7.43M 1.97M 743M 157M
Net income 2022 -31M -8.2M -3.1B -654M Net income 2023 -29M -7.67M -2.9B -612M EV / Sales 2022 -
Net cash position 2022 12.93M 3.42M 1.29B 273M Net cash position 2023 6.46M 1.71M 646M 136M EV / Sales 2023 -
P/E ratio 2022
-0.46 x
P/E ratio 2023
-0.25 x
Employees 2
Yield 2022 *
-
Yield 2023
-
Free-Float 25%
More Fundamentals * Assessed data
Dynamic Chart
Current month+4.53%
1 month+4.53%
3 months-25.00%
6 months-22.25%
Current year-20.75%
More quotes
1 month
47.20
Extreme 47.2
66.50
Current year
47.20
Extreme 47.2
88.00
1 year
40.10
Extreme 40.1
159.30
3 years
40.10
Extreme 40.1
694.00
5 years
40.10
Extreme 40.1
1 180.00
10 years
40.10
Extreme 40.1
1 185.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 19/09/15
Chairman 60 17/05/14
Comptroller/Controller/Auditor 53 30/08/15
Members of the board TitleAgeSince
Director/Board Member 68 28/07/18
Director/Board Member 66 04/07/16
Director/Board Member 53 31/10/17
More insiders
Date Price Change Volume

Delayed Quote TEL AVIV STOCK EXCHANGE, April 25, 2024 at 12:24 pm

More quotes
HBL Hadasit Bio Holdings Ltd (Hadasit) is an investment company, a subsidiary of Hadassah Medical Organization (HMO). The Company’s subsidiaries enable research and development and promote intellectual property (IP) to the medical and biotechnological industries. The Company together with its strategic partners, has established a number of start-up companies, and is assigned to commercialize that IP either through granting a product license to biotechnological or pharmaceutical companies or via the creation of a subsidiary which operates in the premise of HMO. Hadasit is equipped with resources and capabilities required for composing and conducting the pre-clinical services and clinical studies, establishing start-up companies, offering product licensing and providing international consulting services. The Company’s framework serves to address investment in early-stage biotechnological star-ups, by distributing both risk and success amongst a number of companies.
More about the company
  1. Stock Market
  2. Equities
  3. HDST-M Stock